These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
282 related articles for article (PubMed ID: 26529555)
1. INTRAVITREAL BEVACIZUMAB FOR CHOROIDAL NEOVASCULARIZATION IN AGE-RELATED MACULAR DEGENERATION: 5-Year Results of The Pan-American Collaborative Retina Study Group. Arevalo JF; Lasave AF; Wu L; Acón D; Berrocal MH; Diaz-Llopis M; Gallego-Pinazo R; Serrano MA; Alezzandrini AA; Rojas S; Maia M; Lujan S; Retina; 2016 May; 36(5):859-67. PubMed ID: 26529555 [TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration at twenty-four months: the Pan-American Collaborative Retina Study. Arevalo JF; Sánchez JG; Wu L; Berrocal MH; Alezzandrini AA; Restrepo N; Maia M; Farah ME; Brito M; Díaz-Llopis M; Rodríguez FJ; Reategui G; Iturralde-Iraola J; Udaondo-Mirete P; Ophthalmology; 2010 Oct; 117(10):1974-81, 1981.e1. PubMed ID: 20569989 [TBL] [Abstract][Full Text] [Related]
3. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
4. One-year outcomes of less frequent bevacizumab in age-related macular degeneration. Sonmez K; Sonmez PA; Ozkan SS; Atmaca LS Retina; 2011 Apr; 31(4):645-53. PubMed ID: 21358363 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal bevacizumab for treatment-naive patients with subfoveal occult choroidal neovascularization secondary to age-related macular degeneration: a 12-month follow-up study. Costagliola C; Romano M; Corte MD; Perrotta R; Menzione M; Rinaldi M; Semeraro F; Parmeggiani F Retina; 2009 Oct; 29(9):1227-34. PubMed ID: 19934817 [TBL] [Abstract][Full Text] [Related]
6. Intravitreal bevacizumab for previously treated choroidal neovascularization from age-related macular degeneration. Goff MJ; Johnson RN; McDonald HR; Ai E; Jumper JM; Fu A Retina; 2007; 27(4):432-8. PubMed ID: 17420694 [TBL] [Abstract][Full Text] [Related]
7. Treatment of choroidal neovascularization using intravitreal bevacizumab. Pedersen R; Soliman W; Lund-Andersen H; Larsen M Acta Ophthalmol Scand; 2007 Aug; 85(5):526-33. PubMed ID: 17511757 [TBL] [Abstract][Full Text] [Related]
8. Intravitreal bevacizumab in vascular pigment epithelium detachment as a result of subfoveal occult choroidal neovascularization in age-related macular degeneration. Ach T; Hoeh AE; Ruppenstein M; Kretz FT; Dithmar S Retina; 2010 Oct; 30(9):1420-5. PubMed ID: 20543764 [TBL] [Abstract][Full Text] [Related]
9. Intravitreal bevacizumab for the management of choroidal neovascularization in age-related macular degeneration. Bashshur ZF; Bazarbachi A; Schakal A; Haddad ZA; El Haibi CP; Noureddin BN Am J Ophthalmol; 2006 Jul; 142(1):1-9. PubMed ID: 16815245 [TBL] [Abstract][Full Text] [Related]